AMG 706: Phase II data

AMGN reported results from an open-label Phase II trial in 120 evaluable patients with imatinib-resistant disease and said it will no longer develop AMG 706 for

Read the full 263 word article

How to gain access

Continue reading with a
two-week free trial.